Comparative Pharmacology
Head-to-head clinical analysis: FOLEX versus PADCEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLEX versus PADCEV.
FOLEX vs PADCEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
None Documented
None Documented
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with IgG1 clearance.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent